Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections

Br J Haematol. 1996 Apr;93(1):142-5. doi: 10.1046/j.1365-2141.1996.448987.x.

Abstract

Thirty-seven patients with previously treated multiple myeloma (MM) underwent peripheral blood progenitor cell (PBPC) collection following high-dose cyclophosphamide and GM-CSF or sequential IL-3 and GM-CSF. Patients with an inadequate collection were considered for a second or third collection. 25 patients underwent subsequent autotransplant. The only variable predictive of CFU-GM yield was the extent of prior melphalan therapy. All repeat collections were unsuccessful and patients infused with an autograft obtained from multiple sets of collections had a high incidence of delayed engraftment. We conclude that melphalan should be avoided or PBPC collection performed early in the disease course in patients who are potential transplant candidates.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / adverse effects*
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Female
  • Graft Survival
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukapheresis*
  • Male
  • Melphalan / adverse effects*
  • Melphalan / therapeutic use
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / therapy*
  • Specimen Handling / methods
  • Transplantation, Autologous

Substances

  • Antineoplastic Agents, Alkylating
  • Melphalan